Reckitt, the consumer goods giant behind Durex and Lysol, surpassed Q4 like-for-like net sales expectations, reporting 5.4% growth against a 4.7% consensus.
This robust performance was predominantly fueled by a 17.2% surge in emerging markets, notably China and India, marking their tenth consecutive quarter of double-digit expansion. CEO Kris Licht underscored these regions as "must-win" due to their significant growth potential and expanding middle-class populations.
Despite the strong top-line results, Reckitt's shares declined 4.4% as analysts voiced concerns over potential core margin erosion. These worries stem from "stranded costs" linked to the recent $4.8 billion divestiture of the Essential Home division, which are offsetting anticipated margin benefits.
Meanwhile, developed markets, particularly Europe, experienced a 4.5% sales drop, a challenging environment expected to persist into Q1 2026, exacerbated by a milder cold and flu season impacting seasonal over-the-counter products. Reckitt projects its core business to achieve 4-5% like-for-like net revenue growth in 2026, though Q1 growth is anticipated to be below this annual guidance.
Q4 volumes saw a slight decline of 0.2%, and explicit margin guidance for 2026 was not provided.
